在癌症中通过非编码RNA调节血管生成
Zhiyue Su1, Wenshu Li1, Zhe Lei1
1Department of Pathology, The First Affiliated Hospital of Soochow University, Suzhou 215006, China.
Biomolecules
|January 23, 2024
概括
非编码RNAs调节瘤血管生成,这是癌症生长和扩散的关键过程. 向这些RNA为抗血管性癌症疗法提供了一个有希望的新策略.
科学领域:
- 分子生物学分子生物学
- 在瘤学瘤学.
- 遗传学 是一个遗传学.
背景情况:
- 非编码RNAs (ncRNAs),包括microRNAs (miRNAs),长非编码RNAs (lncRNAs) 和圆形RNAs (circRNAs),是基因表达的关键调节者.
- 对ncRNAs的失调越来越多地与瘤血管生成有关,这是瘤生长,转移和癌症死亡率的重要过程.
- 了解ncRNA介导血管生成的分子机制对于开发有效的癌症治疗至关重要.
研究的目的:
- 为提供各种ncRNAs如何调节瘤血管生成的全面概述.
- 讨论使用ncRNAs进行抗血管性癌症治疗的新型治疗策略.
主要方法:
- 关于研究非编码RNA在瘤血管生成中的作用的文献综述.
- 在血管生成中对ncRNA调节的分子机制的分析.
- 探索针对ncRNAs的新兴抗血管原性治疗方法.
主要成果:
- 非编码RNA在通过表观遗传,转录和后转录机制调节血管生成方面发挥着多方面的作用.
- 特定的ncRNA已被确定为促进或抑制各种癌症血管生成的关键参与者.
- 新出现的证据支持ncRNAs作为生物标志物和抗血管性干预的治疗点的潜力.
结论:
- 非编码RNA是瘤血管生成的关键调节者,影响癌症的进展和患者的结果.
- 向ncRNAs代表了开发新型抗血管生成疗法来对抗癌症的有希望的途径.
- 对ncRNA功能和治疗应用的进一步研究是有必要的,以推进癌症治疗策略.
相关概念视频
01:24Regulation of Angiogenesis and Blood Supply
2.6K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.6K
02:39lncRNA - Long Non-coding RNAs
8.6K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.6K
01:10Mechanism of Angiogenesis
5.5K
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
5.5K
01:23Regulation of Expression at Multiple Steps
913
The gene expression in cells is regulated at different stages: (i) transcription, (ii) RNA processing, (iii) RNA localization, and (iv) translation. Transcriptional regulation is mediated by regulatory proteins such as transcription factors, activators, or repressors—these control gene expression by initiating or inhibiting the transcription of genes. Once a precursor or pre-mRNA is produced, it undergoes post-transcriptional modification, including 5' capping, splicing, and the...
913
01:22MicroRNAs
3.0K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.0K
03:03mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K